Abstract
Diabetes and pancreatic ductal adenocarcinoma (PDAC) are common diseases and affect the same organ, pancreas. PDAC has a poor prognosis and response to conservative therapy. Diabetes is recently been correlated with mortality and morbidity from PDAC. The association between diabetes and PDAC stems from the structural association between the endocrine and exocrine pancreas and aberrant expression of hormones from islets. It can also result from other etiological factors including stress, inflammation, smoking, alcohol consumption, change in the diet, as well as inherited syndromes that affect PDAC tissue. Epidemiological evidence suggests that diabetes increases the risk for PDAC development. Insulin resistance, hyperinsulimenia, hyperglycemia, chronic inflammation, and their elementary mechanisms can contribute to the development of diabetes-associated PDAC. Signal transduction pathways that regulate metabolic functions also play a crucial role in the development of PDAC, promoting tumor proliferation, cell growth, differentiation, angiogenesis, and metastasis. In another way, PDAC is also a causative factor for diabetes, although the mechanisms are not well understood. Effective biomarkers might thus help detect the increased risk of PDAC. Furthermore, greater understanding of the pathological mechanisms linking diabetes to PDAC could guide the development of new therapeutic agents to prevent diabetes associated with PDAC.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- 4-HNE:
-
4-hydroxyl-2-nonenal
- Akt:
-
Protein kinase B
- AMP:
-
Adenosine monophosphate
- AMPK:
-
AMP-activated protein kinase
- ATP:
-
Adenosine triphosphate
- ASK-1:
-
Apoptosis signaling kinase-1
- CI:
-
Confidence interval
- COX2:
-
Cyclooxygenase
- DNA:
-
Deoxyribonucleic acid
- ERK:
-
Extracellular signal-regulated kinases
- ETC:
-
electron transport chain
- FGD-PET:
-
F-18-Fluoro-deoxyglucose (FDG)-positron emission tomography (PET)
- FTZ-F1:
-
Fushi-tarazu factor-1
- GI:
-
Glycemic index
- GLUT:
-
Glucose transporter
- GWAS:
-
Genome-wide association studies
- HNF-3β:
-
Hepatocyte nucleoside factor-3β
- IER:
-
Intermittent energy restriction
- IGFBP-1:
-
Insulin growth factor-binding protein-1
- IGF:
-
Insulin growth factor
- IGFR:
-
Insulin growth factor receptors
- IKK:
-
Inhibitor of kB kinase
- IL-6:
-
Interleukin-6
- IL-8:
-
Interleukin-8
- IR:
-
Insulin receptor
- IRS:
-
Insulin receptor substrate 1
- JNK:
-
c-Jun N-terminal kinases
- LKB1:
-
Liver kinase B1
- LOOH:
-
Lipid hydroperoxides
- LRH1:
-
Liver receptor homolog-1
- MDA:
-
Malondialdehyde
- MEK:
-
Mitogen-activated protein kinase
- MMP-7:
-
Matrix metalloproteinase-7
- mTOR:
-
Mammalian target of rapamycin
- NADPH:
-
Nicotinamide adenine dinucleotide
- NF-κB:
-
Nuclear factor kappa B
- NO:
-
Nitric oxide
- NR5A2:
-
Nuclear receptor superfamily member
- PDAC:
-
Pancreatic ductal adenocarcinoma
- PDX-1:
-
Pancreatic duodenal homeobox
- PI3K:
-
Phosphatidylinositol 3 kinase
- RIP-1:
-
Receptor interacting protein
- RO:
-
Alkoxyl radical
- ROS:
-
Reactive oxygen species
- RR:
-
Relative risk
- SO4:
-
Sulfate radical
- SODD:
-
Silencer of death domain
- STAT:
-
Signal transducer and activator of transcription 3
- TNF-α:
-
Tumor necrosis factor-α
- TRADD:
-
TNF receptor-associated death domain
- VAT:
-
Vascular adipose tissue
- VEGF:
-
Vascular endothelial growth factor
References
Becker AE, Hernandez YG, Frucht H, Lucas AL (2014) Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol 20(32):11182–11198
Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O (2018) Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer 18(1):688–688
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29
Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S (2013) SEER cancer statistics review, 1975–2010. National Cancer Institute, Bethesda
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res 74:2913
Sah RP, Nagpal SJS, Mukhopadhyay D, Chari ST (2013) New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 10(7):423–433
Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16(4):1103–1123
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. Diabetes Care 33(7):1674–1685
Aggarwal G, Kamada P, Chari ST (2013) Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 42(2):198–201
Everhart J, Wright D (1995) Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA 273(20):1605–1609
Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H, Li Z (2011) Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 47(13):1928–1937
Silverman DT (2001) Risk factors for pancreatic cancer: A case-control study based on direct interviews. Teratog Carcinog Mutagen 21(1):7–25
Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT (2011) Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 22(2):189–197
Himsworth H, Kerr R (1939) Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 4:119–152
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York, NY) 324(5930):1029–1033
Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JKV, Markowitz S, Zhou S et al (2009) Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (New York, NY) 325(5947):1555–1559
Hine RJ, Srivastava S, Milner JA, Ross SA (2003) Nutritional links to plausible mechanisms underlying pancreatic cancer: a conference report. Pancreas 27(4):356–366
Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM (2008) Glycemic index, glycemic load, and risk of digestive tract neoplasms: a systematic review and meta-analysis. Am J Clin Nutr 89(2):568–576
Reaven GM (1993) Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 44(1):121–131
Lakka H-M, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288(21):2709–2716
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60(4):207–221
Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915
Singh P, Alex JM, Bast F (2014) Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol 31(1):805
Zong CS, Zeng L, Jiang Y, Sadowski HB, Wang L-H (1998) Stat3 plays an important role in oncogenic Ros-and insulin-like growth factor I receptor-induced anchorage-independent growth. J Biol Chem 273(43):28065–28072
Resnicoff M, Baserga R (1998) The Role of the Insulin-like Growth Factor I Receptor in Transformation and Apoptosis. Ann N Y Acad Sci 842(1):76–81
Zeng H, Datta K, Neid M, Li J, Parangi S, Mukhopadhyay D (2003) Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 302(1):46–55
Ding X-Z, Fehsenfeld DM, Murphy LO, Permert J, Adrian TE (2000) Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas 21(3):310–320
Levitt RJ, Pollak M (2002) Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Res 62(24):7372–7376
Hu H, Han T, Zhuo M, Wu LL, Yuan C, Wu L, Lei W, Jiao F, Wang L-W (2017) Elevated COX-2 expression promotes angiogenesis through EGFR/p38-MAPK/Sp1-dependent signalling in pancreatic cancer. Sci Rep 7(1):470
Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak MN (2007) Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res 67(16):7923–7928
Suzuki H, Li Y, Dong X, Hassan MM, Abbruzzese JL, Li D (2008) Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. Cancer Epidemiol Biomark Prev 17(12):3467–3473
Van Kruijsdijk RC, Van Der Wall E, Visseren FL (2009) Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomark Prev 18(10):2569–2578
Ramos EJ, Xu Y, Romanova I, Middleton F, Chen C, Quinn R, Inui A, Das U, Meguid MM (2003) Is obesity an inflammatory disease? Surgery 134(2):329–335
Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296(5573):1634–1635
Parameswaran N, Patial S (2010) Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr 20(2):87–103
Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B: Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 2009, 1171(1):59–76
Heinrich PC, Behrmann I, Serge H, Hermanns HM, Müller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(1):1–20
Hertzer KM, Xu M, Moro A, Dawson DW, Du L, Li G, Chang H-H, Stark AP, Jung X, Hines OJ (2016) Robust Early Inflammation of the Peri-pancreatic Visceral Adipose Tissue During Diet-Induced Obesity in the KrasG12D Model of Pancreatic Cancer. Pancreas 45(3):458
Kalaany NY, Sabatini DM (2009) Tumours with PI3K activation are resistant to dietary restriction. Nature 458(7239):725
Mattson MP, Allison DB, Fontana L, Harvie M, Longo VD, Malaisse WJ, Mosley M, Notterpek L, Ravussin E, Scheer FA (2014) Meal frequency and timing in health and disease. Proc Natl Acad Sci 111(47):16647–16653
Pollak M (2009) Do cancer cells care if their host is hungry? Cell Metab 9(5):401–403
Ogihara T, Asano T, Katagiri H, Sakoda H, Anai M, Shojima N, Ono H, Fujishiro M, Kushiyama A, Fukushima Y (2004) Oxidative stress induces insulin resistance by activating the nuclear factor-κB pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase. Diabetologia 47(5):794–805
Schieber M, Chandel NS (2014) ROS function in redox signaling and oxidative stress. Curr Biol 24(10):R453–R462
Martinez-Useros J, Li W, Cabeza-Morales M, Garcia-Foncillas J (2017) Oxidative stress: a new target for pancreatic cancer prognosis and treatment. J Clin Med 6(3):29
Pani G, Galeotti T, Chiarugi P (2010) Metastasis: cancer cell’s escape from oxidative stress. Cancer Metastasis Rev 29(2):351–378
Bedard K, Krause K-H (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87(1):245–313
Zorov DB, Juhaszova M, Sollott SJ (2014) Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 94(3):909–950
Lee JK, Edderkaoui M, Truong P, Ohno I, Jang KT, Berti A, Pandol SJ, Gukovskaya AS (2007) NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases. Gastroenterology 133(5):1637–1648
Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, Gukovskaya AS (2004) Reactive oxygen species produced by NAD (P) H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem 279(33):34643–34654
Narendhirakannan R, Hannah MAC (2013) Oxidative stress and skin cancer: an overview. Indian J Clin Biochem 28(2):110–115
Bastard J-P, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17(1):4–12
Zhang C, Cao S, Toole BP, Xu Y (2015) Cancer may be a pathway to cell survival under persistent hypoxia and elevated ROS: a model for solid-cancer initiation and early development. Int J Cancer 136(9):2001–2011
Ramanathan B, Jan K-Y, Chen C-H, Hour T-C, Yu H-J, Pu Y-S (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65(18):8455–8460
Fiorini C, Cordani M, Gotte G, Picone D, Donadelli M (2015) Onconase induces autophagy sensitizing pancreatic cancer cells to gemcitabine and activates Akt/mTOR pathway in a ROS-dependent manner. Biochim Biophys Acta 1853(3):549–560
Midaoui AE, Elimadi A, Wu L, Haddad PS, De Champlain J (2003) Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am J Hypertens 16(3):173–179
Tirosh A, Potashnik R, Bashan N, Rudich A (1999) Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-Kinase in 3T3-L1 adipocytes A Putative Cellular Mechanism For Impaired Protein Kinase B activation and glut4 translocation. J Biol Chem 274(15):10595–10602
Andersen DK, Andren-Sandberg Å, Duell EJ, Goggins M, Korc M, Petersen GM, Smith JP, Whitcomb DC (2013) Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas 42(8):1227–1237
Duffy DL (2007) Genetic determinants of diabetes are similarly associated with other immune-mediated diseases. Curr Opin Allergy Clin Immunol 7(6):468–474
Imamura M, Maeda S (2011) Genetics of type 2 diabetes: the GWAS era and future perspectives [Review]. Endocr J 58(9):723–739
Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M et al (2010) A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 42(3):224–228
de Mendonça RL, Bouton D, Bertin B, Escriva H, Noël C, Vanacker J-M, Cornette J, Laudet V, Pierce RJ (2002) A functionally conserved member of the FTZ-F1 nuclear receptor family from Schistosoma mansoni. Eur J Biochem 269(22):5700–5711
Paré J-F, Malenfant D, Courtemanche C, Jacob-Wagner M, Roy S, Allard D, Bélanger L (2004) The fetoprotein transcription factor (FTF) gene is essential to embryogenesis and cholesterol homeostasis and is regulated by a DR4 element. J Biol Chem 279(20):21206–21216
Repa JJ, Mangelsdorf DJ (1999) Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr Opin Biotechnol 10(6):557–563
W-w L, Wang HW, Sum C, Liu D, Hew CL, Chung B (2000) Zebrafish ftz-f1 gene has two promoters, is alternatively spliced, and is expressed in digestive organs. Biochem J 348(2):439–446
Benod C, Vinogradova MV, Jouravel N, Kim GE, Fletterick RJ, Sablin EP (2011) Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation. Proc Natl Acad Sci 108:16927
Lin Q, Aihara A, Chung W, Li Y, Chen X, Huang Z, Weng S, Carlson RI, Nadolny C, Wands JR (2014) LRH1 promotes pancreatic cancer metastasis. Cancer Lett 350(1–2):15–24
Brissova M, Shiota M, Nicholson WE, Gannon M, Knobel SM, Piston DW, Wright CV, Powers AC (2002) Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem 277(13):11225–11232
Ashizawa S, Brunicardi FC, Wang X-P (2004) PDX-1 and the pancreas. Pancreas 28(2):109–120
Annicotte J-S, Fayard E, Swift GH, Selander L, Edlund H, Tanaka T, Kodama T, Schoonjans K, Auwerx J (2003) Pancreatic-duodenal homeobox 1 regulates expression of liver receptor homolog 1 during pancreas development. Mol Cell Biol 23(19):6713–6724
Bell M, Crawford H (2006) The role of PDX-1 in the regulation of the MMP-7 gene expression in pancreatic cancer. In: AACR; 2006
Roy N, Takeuchi KK, Ruggeri JM, Bailey P, Chang D, Li J, Leonhardt L, Puri S, Hoffman MT, Gao S et al (2016) PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. Genes Dev 30(24):2669–2683
Defronzo RA (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58(4):773–795
Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST (2013) Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol 108(4):510
Landman GWD, Kleefstra N, van Hateren KJJ, Groenier KH, Gans ROB, Bilo HJG (2010) Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33(2):322–326
DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3(11):1451–1461. https://doi.org/10.1158/1940-6207.CAPR-10-0157
Currie C, Poole C, Gale E (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9):1766–1777
Li D, Yeung S-CJ, Hassan MM, Konopleva M, Abbruzzese JL (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137(2):482–488
Li D (2012) Diabetes and pancreatic cancer. Mol Carcinog 51(1):64–74
Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schonbeck U, Libby P (2006) Metformin inhibits proinflammatory responses and nuclear factor-κB in human vascular wall cells. Arterioscler Thromb Vasc Biol 26(3):611–617
Gallagher EJ, LeRoith D (2011) Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci 1243(1):54–68
Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F (2012) Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 122(6):253–270
Hadad SM, Fleming S, Thompson AM (2008) Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 67(1):1–7
Shaw RJ, Lamia KA, Vasquez D, Koo S-H, Bardeesy N, Depinho RA, Montminy M, Cantley LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (New York, NY) 310(5754):1642–1646
Batandier C, Guigas B, Detaille D, El-Mir M, Fontaine E, Rigoulet M, Leverve XM (2006) The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr 38(1):33–42
He L, Wondisford FE (2015) Metformin action: concentrations matter. Cell Metab 21(2):159–162
Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30(2):214–226
Williams T, Brenman JE (2008) LKB1 and AMPK in cell polarity and division. Trends Cell Biol 18(4):193–198
He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA, Radovick S, Wondisford FE (2009) Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137(4):635–646
Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang L-S, Jones RG, Choi Y (2009) Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460(7251):103–107
Liang J, Shao SH, Xu Z-X, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL (2007) The energy sensing LKB1–AMPK pathway regulates p27 kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 9(2):218
Li X, Li T, Liu Z, Gou S, Wang C (2017) The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Sci Rep 7(1):5825–5825
Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E (2009) Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69(16):6539–6545
Sadeghi N, Abbruzzese JL, Yeung S-CJ, Hassan M, Li D (2012) Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18(10):2905–2912
Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM (2001) Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120(5):1263–1270
Krisztina K, Aune M, James S-S, Guido E, Enrique R (2013) Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas 42(5):781
Tan X-L, Bhattacharyya KK, Dutta SK, Bamlet WR, Rabe KG, Wang E, Smyrk TC, Oberg AL, Petersen GM, Mukhopadhyay D (2015) Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling. Pancreas 44(4):636–647
Qian W, Li J, Chen K, Jiang Z, Cheng L, Zhou C, Yan B, Cao J, Ma Q, Duan W (2018) Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Life Sci 208:253–261
Sola D, Rossi L, Schianca GPC, Maffioli P, Bigliocca M, Mella R, Corlianò F, Fra GP, Bartoli E, Derosa G (2015) Sulfonylureas and their use in clinical practice. Arch Med Sci 11(4):840
Ashcroft FM (1996) Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 28(09):456–463
Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29(2):254–258
Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E (2009) Sulphonylureas and cancer: a case–control study. Acta Diabetol 46(4):279
Smith U, Gale EAM (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52(9):1699–1708
Gerstein HC (2010) Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA 303(5):446–447
Wang F, Gupta S, Holly EA (2006) Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomark Prev 15(8):1458–1463
Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, Chari ST, Abbruzzese JL (2017) Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes 66(5):1103–1110
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Srivani, G., Dariya, B., Alam, A., Nagaraju, G.P. (2019). Diabetes with Pancreatic Ductal Adenocarcinoma. In: Nagaraju, G., BM Reddy, A. (eds) Exploring Pancreatic Metabolism and Malignancy. Springer, Singapore. https://doi.org/10.1007/978-981-32-9393-9_7
Download citation
DOI: https://doi.org/10.1007/978-981-32-9393-9_7
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9392-2
Online ISBN: 978-981-32-9393-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)